Laura Stampleman

736 total citations
17 papers, 229 citations indexed

About

Laura Stampleman is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Laura Stampleman has authored 17 papers receiving a total of 229 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 8 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Laura Stampleman's work include Multiple Myeloma Research and Treatments (13 papers), Protein Degradation and Inhibitors (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Laura Stampleman is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Protein Degradation and Inhibitors (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Laura Stampleman collaborates with scholars based in United States, China and France. Laura Stampleman's co-authors include Shahrooz Eshaghian, Robert Vescio, James R. Berenson, Regina A. Swift, Jon Arnason, Jennifer R. Brown, Caron A. Jacobson, Youram Nassir, David C. Fisher and Peter Sportelli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Laura Stampleman

17 papers receiving 225 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Stampleman United States 7 115 113 105 94 85 17 229
Alexandra Savell United States 7 78 0.7× 143 1.3× 73 0.7× 98 1.0× 111 1.3× 15 240
Elisa Genuardi Italy 9 114 1.0× 51 0.5× 118 1.1× 110 1.2× 87 1.0× 25 231
Habte Yimer United States 9 106 0.9× 75 0.7× 136 1.3× 156 1.7× 78 0.9× 48 270
Jodi Carey United States 6 75 0.7× 121 1.1× 105 1.0× 87 0.9× 112 1.3× 11 220
Cecilia Arana Yi United States 8 80 0.7× 71 0.6× 100 1.0× 55 0.6× 24 0.3× 21 210
Rose Mantel United States 8 112 1.0× 254 2.2× 98 0.9× 59 0.6× 193 2.3× 13 327
Susan Blumel United States 8 78 0.7× 172 1.5× 60 0.6× 167 1.8× 247 2.9× 16 308
John Hanna United States 4 77 0.7× 210 1.9× 54 0.5× 58 0.6× 139 1.6× 6 262
Monica Testoni Switzerland 4 230 2.0× 36 0.3× 120 1.1× 92 1.0× 87 1.0× 7 321
Juan Garcia‐Talavera Spain 6 75 0.7× 178 1.6× 105 1.0× 67 0.7× 97 1.1× 9 301

Countries citing papers authored by Laura Stampleman

Since Specialization
Citations

This map shows the geographic impact of Laura Stampleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Stampleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Stampleman more than expected).

Fields of papers citing papers by Laura Stampleman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Stampleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Stampleman. The network helps show where Laura Stampleman may publish in the future.

Co-authorship network of co-authors of Laura Stampleman

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Stampleman. A scholar is included among the top collaborators of Laura Stampleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Stampleman. Laura Stampleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Berenson, James R., Tanya M. Spektor, Regina A. Swift, et al.. (2020). A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 26(10). 2346–2353. 25 indexed citations
2.
Berenson, James R., Tanya M. Spektor, Regina A. Swift, et al.. (2019). A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).. Journal of Clinical Oncology. 37(15_suppl). 8048–8048. 1 indexed citations
3.
Davids, Matthew S., Haesook T. Kim, Alexandra Savell, et al.. (2018). Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study. The Lancet Haematology. 6(1). e38–e47. 90 indexed citations
4.
Berenson, James R., Tanya M. Spektor, Regina A. Swift, et al.. (2018). A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients.. Journal of Clinical Oncology. 36(15_suppl). 8005–8005. 3 indexed citations
5.
Berenson, James R., Tanya M. Spektor, Regina A. Swift, et al.. (2018). A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients. Blood. 132(Supplement 1). 1988–1988. 1 indexed citations
6.
Wang, James, Tanya M. Spektor, Jacob D. Bitran, et al.. (2017). Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Supportive Care in Cancer. 25(10). 3217–3224. 2 indexed citations
7.
Spektor, Tanya M., Laura Stampleman, Alberto Bessudo, et al.. (2017). Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma. British Journal of Haematology. 180(1). 60–70. 9 indexed citations
8.
Davids, Matthew S., Karen Francoeur, Hari P. Miskin, et al.. (2017). UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR‐1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL. Hematological Oncology. 35(S2). 54–55. 6 indexed citations
9.
Davids, Matthew S., Haesook T. Kim, Alexandra Savell, et al.. (2016). TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. Blood. 128(22). 641–641. 15 indexed citations
10.
Berenson, James R., Laura Stampleman, Alberto Bessudo, et al.. (2015). Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 33(15_suppl). 8591–8591. 2 indexed citations
11.
Berenson, James, Laura Stampleman, Alberto Bessudo, et al.. (2015). a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 126(23). 5383–5383. 4 indexed citations
12.
Laubach, Jacob P., Noopur Raje, Andrew J. Yee, et al.. (2015). Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM).. Journal of Clinical Oncology. 33(15_suppl). 8579–8579. 2 indexed citations
13.
Berenson, James R., James Hilger, Ori Yellin, et al.. (2014). Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia. 28(7). 1529–1536. 55 indexed citations
14.
Laubach, Jacob P., Noopur Raje, Philippe Armand, et al.. (2014). Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).. Journal of Clinical Oncology. 32(15_suppl). 8534–8534. 1 indexed citations
15.
Berenson, James R., James Hilger, Robert Dichmann, et al.. (2013). Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).. Journal of Clinical Oncology. 31(15_suppl). 8599–8599. 2 indexed citations
16.
Berenson, James R., James Hilger, Robert Dichmann, et al.. (2012). A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen. Blood. 120(21). 4063–4063. 1 indexed citations
17.
Kris, Mark G., et al.. (1987). Preoperative and Adjuvant Chemotherapy in Locally Advanced Non–Small Cell Lung Cancer. Surgical Clinics of North America. 67(5). 1051–1059. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexandra Savell Breakdown of academic impact, for papers by Elisa Genuardi Breakdown of academic impact, for papers by Habte Yimer Breakdown of academic impact, for papers by Jodi Carey Breakdown of academic impact, for papers by Cecilia Arana Yi Breakdown of academic impact, for papers by Rose Mantel Breakdown of academic impact, for papers by Susan Blumel Breakdown of academic impact, for papers by John Hanna Breakdown of academic impact, for papers by Monica Testoni Breakdown of academic impact, for papers by Juan Garcia‐Talavera
Rankless by CCL
2026